Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. DGX
stocks logo

DGX

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Financial AI Agent
Financial AI Agent

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
2.75B
+5.05%
2.357
+5.71%
2.76B
+3.99%
2.363
+6.94%
2.88B
+4.15%
2.757
+5.22%
Estimates Revision
The market is revising Upward the revenue expectations for Quest Diagnostics Incorporated (DGX) for FY2025, with the revenue forecasts being adjusted by 1.1% over the past three months. During the same period, the stock price has changed by 0.38%.
Revenue Estimates for FY2025
Revise Upward
up Image
+1.1%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+0.64%
In Past 3 Month
Stock Price
Go Up
up Image
+0.38%
In Past 3 Month
Wall Street analysts forecast DGX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DGX is 200.78 USD with a low forecast of 190.00 USD and a high forecast of 215.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
11 Analyst Rating
Wall Street analysts forecast DGX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DGX is 200.78 USD with a low forecast of 190.00 USD and a high forecast of 215.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Buy
7 Hold
0 Sell
Moderate Buy
Current: 184.180
sliders
Low
190.00
Averages
200.78
High
215.00
Current: 184.180
sliders
Low
190.00
Averages
200.78
High
215.00
Piper Sandler
Neutral
maintain
$190 -> $200
2025-10-27
Reason
Piper Sandler
Price Target
$190 -> $200
2025-10-27
maintain
Neutral
Reason
Piper Sandler raised the firm's price target on Quest Diagnostics to $200 from $190 following quarterly results. The firm keeps a Neutral rating on the shares.
Morgan Stanley
Erin Wright
Overweight
maintain
$191 -> $207
2025-10-22
Reason
Morgan Stanley
Erin Wright
Price Target
$191 -> $207
2025-10-22
maintain
Overweight
Reason
Morgan Stanley analyst Erin Wright raised the firm's price target on Quest Diagnostics (DGX) to $207 from $191 and keeps an Overweight rating on the shares. Another "beat & raise" quarter was "encouraging," but shares slid as expectations were high and margin pressure was seen in Q3. The firm, which cites a "robust" utilization environment and relative policy insulation for its hiked target, thinks utilization strength should be a positive read for Labcorp's (LH) upcoming report on October 28, but notes that the bar may be raised for labs.
Truist
Hold
maintain
$195 -> $205
2025-10-22
Reason
Truist
Price Target
$195 -> $205
2025-10-22
maintain
Hold
Reason
Truist raised the firm's price target on Quest Diagnostics to $205 from $195 and keeps a Hold rating on the shares. The company posted solid Q3 results ahead of consensus expectations on the top and bottom-lines with FY25 nudged higher as its core trends remain solid with organic volumes ahead of the firm's thinking, better revenue, and a continued tailwind from testing, with the organic revenue guide raised, the analyst tells investors in a research note.
Barclays
Equal Weight
maintain
$190 -> $195
2025-10-22
Reason
Barclays
Price Target
$190 -> $195
2025-10-22
maintain
Equal Weight
Reason
Barclays raised the firm's price target on Quest Diagnostics to $195 from $190 and keeps an Equal Weight rating on the shares post the Q3 report. The company reported "another solid print," the analyst tells investors in a research note. The firm views the post-earnings share selloff as a function of investor positioning given the strength in core tools names and improving sentiment versus moving away from the more defensive labs.
Leerink
Outperform
maintain
$203 -> $210
2025-10-21
Reason
Leerink
Price Target
$203 -> $210
2025-10-21
maintain
Outperform
Reason
Leerink raised the firm's price target on Quest Diagnostics to $210 from $203 and keeps an Outperform rating on the shares. Q3 results were "another proof point of the near-Goldilocks environment in the lab space," according to the analyst, who sees the stock action following "another strong quarter" as more likely a result of rotation than any new fundamental worries.
Jefferies
Buy
maintain
$200 -> $215
2025-10-21
Reason
Jefferies
Price Target
$200 -> $215
2025-10-21
maintain
Buy
Reason
Jefferies raised the firm's price target on Quest Diagnostics to $215 from $200 and keeps a Buy rating on the shares. Sales and EPS beat consensus and fiscal year guidance was raised, notes the analyst, who is "encouraged" by the organic acceleration and "optimistic" for the Haystack MRD test ramp in 2026.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Quest Diagnostics Inc (DGX.N) is 17.91, compared to its 5-year average forward P/E of 15.49. For a more detailed relative valuation and DCF analysis to assess Quest Diagnostics Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Overvalued
5Y Average PE
15.49
Current PE
17.91
Overvalued PE
17.64
Undervalued PE
13.34

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
10.73
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
11.87
Undervalued EV/EBITDA
9.59

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
1.72
Current PS
0.00
Overvalued PS
1.87
Undervalued PS
1.58
Intellectia AI SwingMax
Intellectia AI SwingMax

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders areSelling! The selling amount has increased 4456.93% over the last month.
Sold
Bought
Hedge Fund
Hedge Funds areBuying! The buying amount has increased 1536.08% over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders areSelling! The selling amount has increased 4456.93% over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

DGX News & Events

Events Timeline

(ET)
2025-11-13
11:49:54
Hims & Hers views lab testing as a billion-dollar opportunity, according to WSJ.
select
link
2025-10-27 (ET)
2025-10-27
07:50:18
Quest Diagnostics' AD-Detect Alzheimer's Tests Demonstrate Accuracy in Research Study
select
2025-10-21 (ET)
2025-10-21
06:54:47
Quest Diagnostics increases FY25 adjusted EPS forecast to $9.76-$9.84, up from $9.63-$9.83
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
9.5
11-28NASDAQ.COM
Transcript of Quest (DGX) Q3 2025 Earnings Call
  • Author's Perspective: The views and opinions presented are solely those of the author.
  • No Official Endorsement: The content does not necessarily reflect the views of Nasdaq, Inc.
[object Object]
Preview
3.0
11-27NASDAQ.COM
HOLX vs. DGX: Which Healthcare Diagnostics Stock Offers a Better Investment Opportunity?

  • Hologic and Quest Diagnostics Overview: Hologic specializes in women's health diagnostics, while Quest Diagnostics offers a broader range of affordable testing services across the healthcare ecosystem. Year-to-date, Hologic shares have increased by 3.7%, whereas Quest Diagnostics shares have surged by 25.7%.

  • Hologic's Growth Drivers: Hologic's growth is supported by strong sales in breast health, international market expansion for GYN surgical products, and resilience in molecular diagnostics, including new FDA-approved assays and a focus on the vaginitis market.

  • Quest Diagnostics' Strategic Initiatives: Quest Diagnostics is enhancing its Advanced Diagnostics portfolio, with significant demand for tests like the AD-Detect for Alzheimer's. The company is also pursuing an aggressive acquisition strategy and operational excellence through its Invigorate program, targeting cost savings and productivity improvements.

  • Investment Outlook: Both companies hold a Zacks Rank #3 (Hold), with Quest Diagnostics appearing to be the more attractive investment option due to its impressive year-to-date performance and lower valuation compared to Hologic.

[object Object]
Preview
8.5
11-25Newsfilter
Engine Capital Urges UniFirst Board to Consider Sale for Future Security
  • Shareholder Call: Engine Capital LP, a top five independent common shareholder of UniFirst with approximately 3.2% ownership, publicly urges the board to consider a sale to secure the future for employees, customers, and shareholders, reflecting dissatisfaction with current management.
  • Financial Loss: Since Ron Croatti's passing, UniFirst's stock price has remained flat while competitor Cintas' shares have risen nearly five-fold, indicating significant missteps in value creation by the management that could lead to substantial losses for shareholders and the Croatti family.
  • Governance Issues: Engine Capital questions the board's decision to hold an accelerated virtual annual meeting, arguing that this undermines shareholder rights and transparency, highlighting serious concerns about corporate governance.
  • Strategic Recommendation: The letter notes that former executives unanimously believe a sale is the optimal path forward, emphasizing that the current management's strategic initiatives lack feasibility and may result in further market share losses and declining employee morale.
Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Quest Diagnostics Inc (DGX) stock price today?

The current price of DGX is 184.18 USD — it has increased 0.86 % in the last trading day.

arrow icon

What is Quest Diagnostics Inc (DGX)'s business?

Quest Diagnostics Incorporated is a provider of diagnostic information services. The Company provides diagnostic insights from the results of its laboratory testing to enable people, physicians, and organizations to take action to improve health outcomes. It operates through the DIS segment, which provides diagnostic information services to a range of customers within its primary customer channels: physicians, hospitals, and patients and consumers. It offers broad access to clinical testing through a nationwide network of laboratories, patient service centers, phlebotomists in physician offices, and connectivity resources, including call centers and mobile phlebotomists, nurses and other health and wellness professionals. It also focuses on artificial intelligence (AI) and digital pathology solutions. The Company’s services primarily are provided under the Quest Diagnostics brand and under other brands, including AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum.

arrow icon

What is the price predicton of DGX Stock?

Wall Street analysts forecast DGX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DGX is 200.78 USD with a low forecast of 190.00 USD and a high forecast of 215.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Quest Diagnostics Inc (DGX)'s revenue for the last quarter?

Quest Diagnostics Inc revenue for the last quarter amounts to 2.82B USD, increased 13.18 % YoY.

arrow icon

What is Quest Diagnostics Inc (DGX)'s earnings per share (EPS) for the last quarter?

Quest Diagnostics Inc. EPS for the last quarter amounts to 2.15 USD, increased 8.04 % YoY.

arrow icon

What changes have occurred in the market's expectations for Quest Diagnostics Inc (DGX)'s fundamentals?

The market is revising Upward the revenue expectations for Quest Diagnostics Incorporated (DGX) for FY2025, with the revenue forecasts being adjusted by 1.1% over the past three months. During the same period, the stock price has changed by 0.38%.
arrow icon

How many employees does Quest Diagnostics Inc (DGX). have?

Quest Diagnostics Inc (DGX) has 45000 emplpoyees as of December 05 2025.

arrow icon

What is Quest Diagnostics Inc (DGX) market cap?

Today DGX has the market capitalization of 20.49B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free